Phase 3 N=236 Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis
Uremic Xerosis
Primary: Treatment Response of Xerosis — 71; 48 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=133 Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents
Xerosis Cutis
Primary: Change From Baseline in Overall Dry Skin Score (ODS) — -0.9; -1.2; -0.9 units on a scale
Phase 2 N=200 A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
Dermatitis, Atopic
Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…
N/A N=60 Effectiveness of Using an Oil Bath Additive
Xerosis Cutis
Primary: Transepidermal Water Loss (TEWL) in g/m2/h at the Left Mid Volar Forearm — 10.0; 11.9 g/m2/h — p=0.002
Phase 2 N=19 A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital Ichthyosis
Primary: Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8) — 7; 7; 5; 5 participants
Phase 3 N=51 A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin
Eczema
Primary: Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline — -1.783; -0.767 units on a scale — p=<0.0001
Phase 2 N=51 Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Epidermolysis Bullosa · Epidermolysis Bullosa Simplex
Primary: Treatment-emergent Adverse Events — 40 Participants
N/A N=1,260 A Community-based Assessment of Skin Care, Allergies, and Eczema
Atopic Dermatitis · Atopic Disorders · Eczema
Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019
N/A N=108 Pruritus in Patients With Chronic Kidney Disease
Kidney Failure, Chronic · Pruritus
Primary: Visual Analog Scale (VAS) — 3.35 units on a scale
N/A N=120 Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis
Atopic Dermatitis
Primary: Time to Relapse (Quantile 25%) — 48; 15 Days
Early Phase 1 N=13 An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses
Ichthyosis
Primary: Reduction in Total Ichthyosis Severity Score — -12.2 units on a scale
Phase 4 N=50 A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients
Pruritis
Primary: Severity of Pruritis — 10.88; 9.76; 6.64; 5.12 units on a scale
N/A N=9 Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis · Eczema
Primary: SCORAD Change Score — 33.34 Change Score
Phase 2 N=53 Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema
Atopic Dermatitis
Primary: Change From Baseline in the Itch Assessment Score Immediately Following Treatment — 1.93; 2.64 units on a scale — p=<0.001
Phase 2 N=16 Topical Ruxolitinib in Chronic Hand Dermatitis
Chronic Hand Dermatitis
Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants
Phase 1 N=59 Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment
Healthy
Primary: Frequency Distribution of Skin Irritation Scores — 39; 10; 3; 0 Scores on a scale
N/A N=44 Characterization of Pre-Term Neonatal Skin
Skin Disorder
Primary: Bilirubin Concentration From Non-invasive Diffuse Reflectance Spectroscopy (DRS) vs BiliChek — 0.814386451; 0.85422779; 0.67588721; 0.79293382 Correlation Coefficient…
N/A N=121 A Clinical Investigation With Epaderm® Cream
Eczema · Psoriasis · Dry Skin; Eczema
Primary: Number of Participants With Improved Skin Moisturization — 114 Participants
Phase 2 N=12 Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica
Necrobiosis Lipoidica
Primary: Change in Mean Necrobiosis Lipoidica (NL) Lesion Score — -2.7 score on a scale — p=0.005
Phase 2 N=80 A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris
Ichthyosis Vulgaris
Primary: Treatment Success — 21; 28 Participants
N/A N=150 A Study to Assess the Local Cutaneous and Ocular Tolerance of Three Developmental Facial Skin-care Formulations.
Skin Care
Primary: Number of Participants Determined by a Dermatologist to Have a Clinically Relevant Positive Outcome for Cutaneous Irritation After 21 Days of Product Use — 1; 0; 0…
N/A N=21 The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease
Uremic Pruritus
Primary: Visual Analogue Scale (VAS) Score for Pruritus — -3.38; -3.53 Units on a scale — p=<0.05
Phase 4 N=25 VANOS Cream and Skin Barrier Function
Atopic Dermatitis
Primary: Change in Eczema Severity and Area Index — 6.01 units — p=<0.01
N/A N=149 To Evaluate the Effect of Moisturizing Creams on Skin Barrier Function
Dry Skin · Skin Care
Primary: Change From Baseline in Trans-epidermal Water Loss (TEWL) Following Application of Test Regimen on Face (Area 1 Compared to Area 2) at Day 29 — -5.077; -4.946; -3.692…
N/A N=41 Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
Atopic Dermatitis (AD)
Primary: Percentage With Erythema on the Face at Baseline Before Investigational Product Application — 33.3; 71.9; 55.6; 6.3 Percentage of participants
Phase 2 N=21 Topical Cyclosporine Suspension for the Treatment of Brittle Nails
Brittle Nail Syndrome
Primary: • Number of Patients Receiving at Least a 1-grade Improvement in the Physicians Global Improvement Assessment (PGIA) of Two Target Nails. — 10; 11 patients
Phase 4 N=20 A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change of Trans Epidermal Water Loss (TEWL) With Use of Eucerin Lotion — 21.4 percent change
N/A N=60 Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
Phase 3 N=596 Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
Eczema
Primary: Number of Participants Who Responded as Per Physician's Global Assessment (PGA) at Week 24 — 58; 14; 60; 30 Participants — p=<0.001
Phase 2 N=12 A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
Sjögren-Larsson Syndrome
Primary: Number of Participants Experiencing a Serious Adverse Event (SAE). — 0; 0 Participants